P. Ennezat, R. Guerbaai, Thierry H. LeJemtel, Morten Rix Hansen
{"title":"替卡格雷在冠状动脉疾病中的试验应完全透明","authors":"P. Ennezat, R. Guerbaai, Thierry H. LeJemtel, Morten Rix Hansen","doi":"10.1080/21548331.2022.2049099","DOIUrl":null,"url":null,"abstract":"Cardiology department, Service de cardiologie, Centre Hospitalier Universitaire Henri Mondor, Créteil, France; Medizinische Fakultät, Department Public Health (DPH), Universität Basel, Basel, Switzerland; University Heart and Vascular Institute, New Orleans, LA, USA; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark","PeriodicalId":75913,"journal":{"name":"Hospital practice","volume":"50 1","pages":"89 - 92"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Full transparency of ticagrelor trials in coronary artery disease should be warranted\",\"authors\":\"P. Ennezat, R. Guerbaai, Thierry H. LeJemtel, Morten Rix Hansen\",\"doi\":\"10.1080/21548331.2022.2049099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiology department, Service de cardiologie, Centre Hospitalier Universitaire Henri Mondor, Créteil, France; Medizinische Fakultät, Department Public Health (DPH), Universität Basel, Basel, Switzerland; University Heart and Vascular Institute, New Orleans, LA, USA; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark\",\"PeriodicalId\":75913,\"journal\":{\"name\":\"Hospital practice\",\"volume\":\"50 1\",\"pages\":\"89 - 92\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21548331.2022.2049099\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21548331.2022.2049099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Full transparency of ticagrelor trials in coronary artery disease should be warranted
Cardiology department, Service de cardiologie, Centre Hospitalier Universitaire Henri Mondor, Créteil, France; Medizinische Fakultät, Department Public Health (DPH), Universität Basel, Basel, Switzerland; University Heart and Vascular Institute, New Orleans, LA, USA; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark